Javier Angulo Cuesta-rekin lankidetzan egindako argitalpenak (52)

2024

  1. Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis

    Immuno-Oncology and Technology, Vol. 21

  2. Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients

    International Journal of Molecular Sciences, Vol. 25, Núm. 13

  3. Predicting Survival of Metastatic Clear Cell Renal Cell Cancer Treated with VEGFR-TKI-Based Sequential Therapy

    Cancers, Vol. 16, Núm. 16

  4. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

    European urology oncology, Vol. 6, Núm. 1, pp. 58-66

2022

  1. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466

2021

  1. (Pro)renin receptor is a novel independent prognostic marker in invasive urothelial carcinoma of the bladder

    Cancers, Vol. 13, Núm. 22

  2. Clinical implications of (Pro)renin receptor (prr) expression in renal tumours

    Diagnostics, Vol. 11, Núm. 2

  3. Soluble pd-l1 is an independent prognostic factor in clear cell renal cell carcinoma

    Cancers, Vol. 13, Núm. 4, pp. 1-17

2020

  1. Altered tissue and plasma levels of fibroblast activation protein-α (FAP) in renal tumours

    Cancers, Vol. 12, Núm. 11, pp. 1-16

2019

  1. A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

    Current Urology Reports, Vol. 20, Núm. 1

  2. Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology

    npj Precision Oncology, Vol. 3, Núm. 1

  3. Precise immunodetection of PTEN protein in human neoplasia

    Cold Spring Harbor Perspectives in Medicine, Vol. 9, Núm. 12

  4. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder

    Human Pathology, Vol. 91, pp. 61-68

2018

  1. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma

    Annals of Diagnostic Pathology, Vol. 34, pp. 27-30

  2. Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma

    Annals of Diagnostic Pathology, Vol. 34, pp. 89-93

  3. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy

    Pathology Research and Practice, Vol. 214, Núm. 8, pp. 1110-1114

2017

  1. CD34 immunostaining enhances a distinct pattern of intratumor angiogenesis with prognostic implications in clear cell renal cell carcinoma

    APMIS, Vol. 125, Núm. 2, pp. 128-133

2016

  1. Estudio retrospectivo de diferentes opciones de tratamiento conservador con Bacilo de Calmette-Guèrin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento

    Actas Urologicas Espanolas, Vol. 40, Núm. 6, pp. 370-377

  2. Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma

    Human Pathology, Vol. 54, pp. 100-105